Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.36 |
| ▸ | SGK1 | O00141 | 12/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29829479 | 1.00 | CCR2 (0.36) | CCR2SLC40A1SGK1CYP2C9CYP2C19 | |
| SCHEMBL29829927 | 0.90 | SLC40A1 (0.38) | CCR2SLC40A1SGK1CYP2C9CYP2C19 | |
| SCHEMBL21596699 | 0.90 | SLC40A1 (0.38) | CCR2SLC40A1SGK1CYP2C9CYP2C19 | |
| SCHEMBL21596692 | 0.89 | — | — | |
| SCHEMBL23620167 | 0.86 | PIK3CA (0.32) | CCR2SLC40A1SGK1CYP2C9CYP2C19 | |
| SCHEMBL21596672 | 0.85 | SGK1 (0.42) | CCR2SLC40A1SGK1 | |
| SCHEMBL29829666 | 0.85 | SGK1 (0.42) | CCR2SLC40A1SGK1 | |
| SCHEMBL21545846 | 0.84 | CCR2 (0.38) | CCR2SLC40A1SGK1 | |
| SCHEMBL30286509 | 0.84 | CCR2 (0.38) | CCR2SLC40A1SGK1 | |
| SCHEMBL23620168 | 0.82 | PIK3CA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112469710-B | Pyridyl and pyrazinyl- (aza) indole sulfonamides | 优时比制药有限公司 | 2024-05-14 | — | — | CN | claimed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | claimed |
| EP-3810591-B1 | PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2022-08-10 | — | — | EP | claimed |
| US-20210206749-A1 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | UCB PHARMA GMBH (DE) | 2021-07-08 | — | — | US | claimed |
| CN-112469710-A | Pyridyl and pyrazinyl- (aza) indole sulfonamides | 优时比制药有限公司 | 2021-03-09 | — | — | CN | claimed |
| CN-112469710-B | Pyridyl and pyrazinyl- (aza) indole sulfonamides | 优时比制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| EP-4074703-B1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| EP-4074703-B1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| EP-4074703-A1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB Pharma GmbH (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-4074703-A1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB Pharma GmbH (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-3810591-B1 | PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2022-08-10 | — | — | EP | disclosed |
| US-20210206749-A1 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | UCB PHARMA GMBH (DE) | 2021-07-08 | — | — | US | disclosed |
| US-20210206749-A1 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | UCB PHARMA GMBH (DE) | 2021-07-08 | — | — | US | disclosed |
| EP-3810591-A1 | PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES | UCB Pharma GmbH (DE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112469710-A | Pyridyl and pyrazinyl- (aza) indole sulfonamides | 优时比制药有限公司 | 2021-03-09 | — | — | CN | disclosed |
| WO-2019243303-A1 | PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206749-A1 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | GPR17, GPR18, GPR119 | CCR2 916/4885SLC40A1 3700/4885SGK1 1683/4885 |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | GPR17, GPR18, GPR119 | CCR2 916/4885SLC40A1 3700/4885SGK1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.